Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS(2025) Protein profiles predict treatment responses to the PI3K inhibitor umbralisib in patients with chronic lymphocytic leukemia Clin Cancer Res(in press) DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050
Wei Q, Foyn H, Landskron J, Wang S, Rye IH, Skånland SS, Russnes HEG, Klaveness J, Ahmad R, Taskén K(2025) Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3 iScience, 28(3), 111931 DOI 10.1016/j.isci.2025.111931, PubMed 40034859
Arseni L, Sigismondo G, Yazdanparast H, Hermansen JU, Mack N, Ohl S, Kalter V, Iskar M, Kalxdorf M, Friedel D, Rettel M, Paul Y, Ringshausen I, Eldering E, Dubois J, Kater AP, Zapatka M, Roessner PM, Tausch E, Stilgenbauer S, Dietrich S, Savitski MM, Skånland SS, Krijgsveld J, Lichter Pet al.(2025) Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL Nat Commun, 16(1), 1041 DOI 10.1038/s41467-025-56318-7, PubMed 39863584